Get the Stockscreener App
27.16
2.86%
-0.80
After Hours:
27.16
Maplight Therapeutics Inc stock is traded at $27.16, with a volume of 203.07K.
It is down -2.86% in the last 24 hours and down -5.46% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$27.96
Open:
$27.97
24h Volume:
203.07K
Relative Volume:
0.69
Market Cap:
$1.23B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-7.3111
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
-7.21%
1M Performance:
-5.46%
6M Performance:
+33.46%
1Y Performance:
+0.00%
1-Day Range:
$26.73
$28.57
1-Week Range:
$26.73
$31.28
52-Week Range:
$12.24
$33.28
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
27.16 | 1.27B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
MapLight Therapeutics (MPLT) Surges 3.31% as Positive Momentum BuildsHull Moving Average - newsline.com
MPLT Q1 2026 Earnings: EPS Misses Estimates by 20% as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
MapLight Therapeutics (MPLT) Drops Over 6% as Key Support Level NearsVWAP Breakout - newsline.com
What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data - AOL.com
MPLT Maintained by Stifel -- Price Target Raised to $36.00 - GuruFocus
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Raises Target Price to $36 - Moomoo
Stifel raises MapLight Therapeutics price target on drug potential By Investing.com - Investing.com Canada
MPLT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - AOL.com
MPLT Options Volatility — NASDAQ:MPLT - TradingView
MPLT Options Chain — NASDAQ:MPLT - TradingView
MapLight Stock Slips Ahead of August Drug Update - Bez Kabli
MPLT Q1 2026 Earnings: Wider-than-Expected Loss Reflects Continued Development SpendingEarnings Call Q&A - The Legal Advocate
MPLT Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
MPLT Initiated Coverage by UBS -- Rating Set to Buy, Target at $48 - GuruFocus
MapLight Therapeutics Rises 2.4%, Nearing Key Resistance Level (MPLT)Resistance Breakout Stocks - The Legal Advocate
MapLight Therapeutics (MPLT) Tests Key Support After 1.8% DeclineSeasonality Effect - The Legal Advocate
Nan Fung Group Holdings Ltd's MapLight Therapeutics Inc(MPLT) Holding History - GuruFocus
MPLT Initiated Coverage On by Craig-Hallum -- Rating Set to Buy - GuruFocus
MapLight Therapeutics (MPLT) Q1 2026 Stumbles — EPS $-1.34 Misses TargetPro Trader Picks - Newser
Craig-Hallum initiates MapLight Therapeutics stock with buy rating By Investing.com - Investing.com Canada
MapLight Therapeutics Q1 2026 Earnings: Wider Loss than Anticipated, Yet Shares Climb on Pipeline OptimismRevenue Surprise History - The Legal Advocate
Analyst Reiterates Buy on MapLight, Maintains $37 Price Target on Confidence in ML-007 and Pipeline Upside - TipRanks
MapLight's psychosis drug could deliver billion-dollar upside, says analyst - MSN
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock By Investing.com - Investing.com Nigeria
MapLight Therapeutics Insider Sold Shares Worth $3,215,000, According to a Recent SEC Filing - Moomoo
MapLight Therapeutics CEO Christopher Kroeger sells $3.2m in stock - Investing.com
MapLight Therapeutics (MPLT) CEO sells 118K shares in pre-planned trades - Stock Titan
MapLight Therapeutics, Inc.Common Stock (NQ: MPLT - The Chronicle-Journal
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? - The Motley Fool
Buy Rating Reiterated on Clinical Catalysts and Strong Cash Runway; $37 Price Target Unchanged - TipRanks
T. Rowe Price (NASDAQ: MPLT) discloses 7.4% position in MapLight Therapeutics - Stock Titan
A Quick Look at Today's Ratings for MapLight Therapeutics(MPLT.US), With a Forecast Between $35 to $45 - Moomoo
MPLT SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MapLight Therapeutics, Inc. Stock 12‑Month Price Target Raised to $36, Implies 23% Upside - TradingView
MapLight (MPLT) Reports Progress in Clinical Trials and Early-St - GuruFocus
MapLight Therapeutics Expands Pipeline Amid Rising Quarterly Losses - TipRanks
MapLight Therapeutics 1Q Loss/Shr $1.34 >MPLT - Moomoo
TradingKey - TradingKey
[10-Q] MapLight Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
MapLight Therapeutics (MPLT) widens Q1 loss as key Phase 2 readouts near - Stock Titan
What $395M in cash means for MapLight’s schizophrenia, autism trials - Stock Titan
MapLight Therapeutics (MPLT) Q4 2025 Earnings: Miss Sparks ConcernNet Profit Margin - newsline.com
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | General Counsel |
May 11 '26 |
Sale |
30.13 |
13,917 |
419,263 |
162,331 |
| Kroeger Christopher A. | Chief Executive Officer |
May 08 '26 |
Sale |
27.69 |
34,411 |
952,835 |
1,526,309 |
| Kroeger Christopher A. | Chief Executive Officer |
May 07 '26 |
Sale |
28.65 |
20,100 |
575,797 |
1,560,720 |
| Kroeger Christopher A. | Chief Executive Officer |
May 11 '26 |
Sale |
30.11 |
13,980 |
421,002 |
1,512,329 |
| Foff Erin Pennock | Chief Medical Officer |
May 07 '26 |
Sale |
28.54 |
4,438 |
126,640 |
346,059 |
| Lillie James Woodruff | Chief Scientific Officer |
May 07 '26 |
Sale |
28.28 |
721 |
20,390 |
242,729 |
| Setia Vishwas | Chief Financial Officer |
May 04 '26 |
Sale |
28.11 |
14,904 |
418,930 |
377,723 |
| Setia Vishwas | Chief Financial Officer |
May 05 '26 |
Sale |
28.20 |
10,903 |
307,444 |
366,820 |
| Setia Vishwas | Chief Financial Officer |
May 06 '26 |
Sale |
28.24 |
10,564 |
298,345 |
356,256 |
| Foff Erin Pennock | Chief Medical Officer |
May 06 '26 |
Sale |
28.76 |
24,052 |
691,749 |
350,497 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):